利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

38 条记录 (耗时 0.012 秒)

    TREATMENT OF FEMALE SEXUAL DYSFUNCTION
    11.
    发明公开
    TREATMENT OF FEMALE SEXUAL DYSFUNCTION 审中-公开
    治疗女性性功能障碍的

    公开(公告)号：EP1056419A1

    公开(公告)日：2000-12-06

    申请号：EP99905497.6

    申请日：1999-01-28

    申请人： PENTECH PHARMACEUTICALS, INC.

    发明人： EL-RASHIDY, Ragab ,  RONSEN, Bruce

    IPC分类号： A61F6/06

    CPC分类号： A61K31/485

    摘要： Sexual dysfunction in human females can be ameliorated, without substantial undesirable side effects, by sublingual administration of apomorphine dosage forms. Administration of apomorphine increases nerve stimulated clitoral intracavernosal blood flow and vaginal wall blood flow for enhanced clitoral erection and vaginal engorgement in a female. A plasma concentration of apomorphine of no more than about 5.5 nanograms per milliliter is preferably maintained.

    APOMORPHINE AND SILDENAFIL COMPOSITION
    13.
    发明公开
    APOMORPHINE AND SILDENAFIL COMPOSITION 有权
    含阿朴吗啡和西地那非及其使用用于治疗勃起功能障碍的组合物

    公开(公告)号：EP1173178A1

    公开(公告)日：2002-01-23

    申请号：EP00916324.7

    申请日：2000-03-14

    申请人： Pentech Pharmaceuticals, Inc.

    发明人： EL-RASHIDY, Ragab

    IPC分类号： A61K31/44 ,  A61K31/505

    CPC分类号： A61K31/505 ,  A61K31/47 ,  A61K2300/00

    摘要： The treatment of sexual dysfunction in human patients by an oral therapy regimen of administration of apomorphine and sildenafil is disclosed. This treatment optimizes the efficacy of each drug and substantially minimizes the undesirable side effects associated individually therewith. Apomorphine and sildenafil can be co-administered with a combination dosage unit or administered sequentially in separate dosage units, substantially prior to sexual activity. Other erectogenic agents can be administered along with apomorphine and sildenafil.

    PROCESS FOR PREPARING ARYLPIPERIDINE CARBINOL INTERMEDIATES AND DERIVATIVES
    14.
    发明公开
    PROCESS FOR PREPARING ARYLPIPERIDINE CARBINOL INTERMEDIATES AND DERIVATIVES 审中-公开
    用于生产ARYLPIPERIDINCARBINOL中间体及其衍生物

    公开(公告)号：EP1140832A1

    公开(公告)日：2001-10-10

    申请号：EP99966475.8

    申请日：1999-12-17

    申请人： PENTECH PHARMACEUTICALS, INC.

    发明人： RONSEN, Bruce ,  UPADHYAYA, Subhash, P.

    IPC分类号： C07D211/22 ,  C07D211/78 ,  C07C255/41

    CPC分类号： C07C255/41 ,  C07B2200/07 ,  C07D211/78

    摘要： A process for the synthesis of arylpiperidine carbinol intermediates and derivatives is disclosed. A preferred process embodiment provides the synthesis of intermediate compounds of structural formula (I) and structural formula (II), where X is halogen, C1-C10 alkyl, C1-C10 alkoxy, C1-C10 haloalkyl, hydroxy, or hydrogen; and R2 and R3 each is C1-C4 alkyl and R2 and R3 are the same. The compound of structural formula (I) is made by condensing a corresponding cinnamonitrile with a corresponding diester malonate. The compound of structural formula (II) in the (±)-trans configuration is obtained by hydrogenating the compound of structural formula (I). The compounds of structural formula (I) and structural formula (II) are useful chemical intermediates for synthesizing 4-arylpiperidine-3-carbinols and their derivatives in (-)-trans configuration.

    AMELIORATION OF APOMORPHINE ADVERSE EFFECTS
    15.
    发明公开
    AMELIORATION OF APOMORPHINE ADVERSE EFFECTS 审中-公开
    还原阿朴吗啡不必要的副作用

    公开(公告)号：EP1105129A1

    公开(公告)日：2001-06-13

    申请号：EP99933642.3

    申请日：1999-07-01

    申请人： PENTECH PHARMACEUTICALS, INC.

    发明人： EL-RASHIDY, Ragab ,  RONSEN, Bruce

    IPC分类号： A61K31/44

    CPC分类号： A61K31/473

    摘要： Symptoms of Parkinson's disease and psychogenic male erectile dysfunction (MED) can be ameliorated through the use of apomorphine. The adverse side effects of apomorphine administration, such as nausea, vomiting, yawning, and cardiovascular effects, can be significantly reduced by a dose escalating method of acclimatization. An initial dose of apomorphine is administered to the patient, and subsequently increased over a period of time until a final apomorphine dose in excess of a desired therapeutic dose has been received by the patient. Thereafter a therapeutic dose of apomorphine, less than the final apomorphine dose, is administered to the patient with attendant reduced side effects.

    AMORPHOUS PAROXETINE COMPOSITION
    18.
    发明公开
    AMORPHOUS PAROXETINE COMPOSITION 审中-公开
    编制非晶帕罗西汀

    公开(公告)号：EP1019053A1

    公开(公告)日：2000-07-19

    申请号：EP98951989.7

    申请日：1998-09-30

    申请人： PENTECH PHARMACEUTICALS, INC.

    发明人： RONSEN, Bruce ,  EL-RASHIDY, Ragab

    IPC分类号： A61K31/445 ,  A61K9/00 ,  A61K9/16 ,  A61K9/20

    CPC分类号： A61K31/4525 ,  A61K9/145 ,  A61K9/146 ,  C07D401/12

    摘要： A free-flowing, amorphous paroxetine hydrochloride composition suitable as a therapeutic agent for premature ejaculation can be prepared by dissolving paroxetine free base in a hydrochloric acid-ethanol solution followed by drying. The present compositions comprise amorphous paroxetine hydrochloride and at least one hydroxyl-bearing compound. In one preferred embodiment, the hydroxyl-bearing compound is ethanol and the amount of ethanol present in the amorphous product is in the range of 1 to 4 weight percent based on paroxetine hydrochloride. The amorphous product is stable and substantially non-hygroscopic.